VHB937

Phase 2Biologic

Novartis

VHB937 is one of 61 biologic programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Alzheimer's DiseaseRecruiting

Amyotrophic Lateral Sclerosis (ALS)Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Alzheimer's DiseasePhase 2

Recruiting

Amyotrophic Lateral Sclerosis (ALS)Phase 2

Active, not recruiting

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

Ultomiris

Robitussin

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 7

Minocin

TTriax

Phase 3

2 8

Sodium Valproate

AstraZeneca

Phase 3

1 9

BOTULINUM TOXIN TYPE B

Eisai

Phase 3

1 10

Namenda

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Amyotrophic Lateral Sclerosis (ALS)

NCT06643481

Q4 2030

Phase 2Recruiting

Alzheimer's Disease

NCT07094516

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06643481·251 enrolled

Alzheimer's Disease1 trial

A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension

Recruiting· Novartis logo

Novartis·Phase 2·NCT07094516·407 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VHB937. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VHB937 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VHB937. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Novartis

VHB937

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2030

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News